Cargando…
Rucaparib and Niraparib in Advanced Ovarian Cancer
Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy in previously treated ovarian cancers, with niraparib demonstrating acti...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520743/ https://www.ncbi.nlm.nih.gov/pubmed/33343988 http://dx.doi.org/10.6004/jadpro.2019.10.4.8 |